Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Balslev

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Breast (Edinburgh, Scotland)|September 27, 2018
Risk factors of sentinel and non-sentinel lymph node metastases in patients with ductal carcinoma in situ of the breast: A nationwide studyEmil Villiam Holm-Rasmussen, Maj-Britt Jensen, Eva Balslev, et al.
Breast Cancer Research and Treatment|December 10, 2014
Reduced risk of axillary lymphatic spread in triple-negative breast cancerEmil Villiam Holm-Rasmussen, Maj-Britt Jensen, Eva Balslev, et al.
Breast Cancer Research and Treatment|September 6, 2015
Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide studyTove Filtenborg Tvedskov, Maj-Britt Jensen, Bent Ejlertsen, et al.
Cellular Oncology (Dordrecht, Netherlands)|July 17, 2014
Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node statusLene Rask, Eva Balslev, Rolf Søkilde, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2017
The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based studyEmil Villiam Holm-Rasmussen, Maj-Britt Jensen, Eva Balslev, et al.
International Journal of Cancer|February 21, 2012
High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel nodeTove Filtenborg Tvedskov, Maj-Britt Jensen, Ida Marie Lisse, et al.
International Journal of Breast Cancer|January 3, 2014
Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic TestingTim S Poulsen, Maiken L M Espersen, Vibeke Kofoed, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|August 30, 2020
Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISHSteffen Grann Jensen, Peter Engel Thomas, Ib Jarle Christensen, et al.
Breast (Edinburgh, Scotland)|May 21, 2008
Intraoperative immunohistochemistry staining of sentinel nodes in breast cancer: clinical and economical implicationsMarianne Holm, Birgitte Paaschburg, Eva Balslev, et al.
BMC Cancer|June 15, 2019
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I geneIben Kümler, Eva Balslev, Jan Stenvang, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Breast (Edinburgh, Scotland)|September 27, 2018
Risk factors of sentinel and non-sentinel lymph node metastases in patients with ductal carcinoma in situ of the breast: A nationwide studyEmil Villiam Holm-Rasmussen, Maj-Britt Jensen, Eva Balslev, et al.
Breast Cancer Research and Treatment|December 10, 2014
Reduced risk of axillary lymphatic spread in triple-negative breast cancerEmil Villiam Holm-Rasmussen, Maj-Britt Jensen, Eva Balslev, et al.
Breast Cancer Research and Treatment|September 6, 2015
Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide studyTove Filtenborg Tvedskov, Maj-Britt Jensen, Bent Ejlertsen, et al.
Cellular Oncology (Dordrecht, Netherlands)|July 17, 2014
Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node statusLene Rask, Eva Balslev, Rolf Søkilde, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2017
The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based studyEmil Villiam Holm-Rasmussen, Maj-Britt Jensen, Eva Balslev, et al.
International Journal of Cancer|February 21, 2012
High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel nodeTove Filtenborg Tvedskov, Maj-Britt Jensen, Ida Marie Lisse, et al.
International Journal of Breast Cancer|January 3, 2014
Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic TestingTim S Poulsen, Maiken L M Espersen, Vibeke Kofoed, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|August 30, 2020
Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISHSteffen Grann Jensen, Peter Engel Thomas, Ib Jarle Christensen, et al.
Breast (Edinburgh, Scotland)|May 21, 2008
Intraoperative immunohistochemistry staining of sentinel nodes in breast cancer: clinical and economical implicationsMarianne Holm, Birgitte Paaschburg, Eva Balslev, et al.
BMC Cancer|June 15, 2019
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I geneIben Kümler, Eva Balslev, Jan Stenvang, et al.
Pageof 9